Immunotherapy combo before liver surgery shows promise for advanced colorectal cancer
NCT ID NCT03844750
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two drugs, pembrolizumab and vactosertib, given before and after surgery to remove liver tumors in people with colorectal cancer that had spread to the liver. The goal was to see if these drugs could shrink the liver tumors before surgery and lower the chance of cancer coming back after surgery. The study was stopped early and included only 6 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new blood test spot colorectal cancer return earlier?
- Experimental drug combo targets Hard-to-Treat GI cancers
- Double immunotherapy plus liver blockade targets eye cancer that spreads
- Wheat germ supplement studied for immune boost in advanced cancer
- Could a pill help the liver regrow and make more cancer surgeries possible?
- Can a smaller dose of this cancer drug still work? new trial aims to find out